Document is current

Article History

Received: 21 June 2024

Accepted: 24 July 2024

First Online: 1 August 2024

Declarations

:

: This study complies with the Helsinki Declaration of 1975, as revised in 2008. The study was reviewed by the Medical Ethics Committee of the VU University Medical Center, Amsterdam UMC (2021.0228). All participants provided written informed consent to participate in the study, and to publish unidentifiable data.

: FB is a member of the steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai and Prothena, an advisory board member for Combinostics, Scottish Brain Sciences, a consultant for Roche, Celltrion, Rewind Therapeutics, Merck, Bracco. FB has research agreements with ADDI, Merck, Biogen, GE Healthcare, Roche, and is a co-founder and shareholder of Queen Square Analytics LTD. JR and WS are employees of and share holders in Cambridge Cognition (and previously, Winterlight Labs). JH is an employee and share holder in Scottish Brain Sciences and a paid consultant to Cambridge Cognition, owners of the the Winterlight system.SS is a scientific advisory board member of Prothena Biosciences and Cogstate, provides consultancy services to Aribio Co LTD and Biogen, and receives license fees from Brain Research Center, Green Valley, VtV Therapeutics, Alzheon, Vivoryon and Roche, and the developer of the Amsterdam IADL. All license fees are for the organization.Research programs of WF have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF is recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003). TAP-dementia receives co-financing from Avid Radiopharmaceuticals and Amprion. All funding is paid to her institution. WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funding is paid to her institution. WF is member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. No other competing interests were reported.